Navigation Links
Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Date:9/14/2009

MOUNTAIN VIEW, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced preliminary results from its 366 patient Phase 2b clinical trial of AZ-104 (Staccato(R) loxapine) in patients with migraine headache. Both AZ-104 dose groups trended towards statistical significance, but the study did not meet its primary endpoint, which was defined as pain-relief at the 2-hour time point, compared to placebo. There were no serious adverse events in the clinical trial, and AZ-104 was generally safe and well tolerated in this patient population.

"The failure to reach statistical significance on the primary endpoint is disappointing, as we were not able to reproduce the positive clinical findings from our AZ-104 Phase 2a proof-of-concept clinical trial," said James V. Cassella, PhD, Senior Vice President, Research and Development at Alexza. "Loxapine is a drug that had not been previously studied in migraine patients, except for our earlier proof-of-concept study. As part of our collaboration with Symphony Allegro, we initiated this migraine program in 2007 to investigate whether loxapine might be a viable product candidate for migraine, due to the scientific rationale that loxapine's primary mechanism of action (dopamine antagonism) has shown effectiveness in treating migraine."

"We continue to be impressed with Staccato's ability to safely and very accurately deliver a portfolio of drugs in a simple, one-breath, patient-controlled inhalation," said Thomas B. King, President and CEO of Alexza. "The uniqueness of our Staccato technology allows us to examine medicines for both known and new indications, and we will continue to do so in a patient setting. Not every clinical trial will necessarily have posit
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Anthem Blue ... that would have required them to obtain their medications ... Consumer Watchdog and Whatley Kallas LLC.  ... Court, alleged that Blue Cross,s mandatory mail order program ... their health and privacy. "This settlement brings ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
(Date:5/23/2013)... , May 23, 2013  Ameritox, the ... selected by Progressive Medical, Inc. to become part ... help clients manage pharmacy costs and improve the ... Medical, a leading pharmacy benefit manager in the ... overall medication compliance and pain management strategy for ...
Breaking Medicine Technology:Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3
... 2011 GlaxoSmithKline (GSK) is committed to ensuring that ... and alli. alli is safe and effective when used ... and works locally in the gastro-intestinal tract. GSK continues ... share all relevant information with regulatory agencies. ...
... April 14, 2011 Freedom Innovations, a company ... lower extremity prosthetic devices, today announced a worldwide ... rights to commercialize the world,s first lower extremity ... that operate synergistically.  Developed at the Vanderbilt University ...
Cached Medicine Technology:Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 2Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 3
(Date:5/24/2013)... York (PRWEB) May 24, 2013 ... DePuy hip recall continue to move forward in courts ... to documents filed in California’s San Francisco Superior Court ... an expedited trial of her DePuy hip lawsuit is ... DePuy Orthopaedics, Inc., et al., No. CGC11508806; Calif. Super. ...
(Date:5/24/2013)... Western University of Health Sciences’ College of Veterinary ... the next seven years from the American Veterinary Medical ... a magnificent achievement, and one we expected as a ... College of Veterinary Medicine Dean Phillip Nelson, DVM, PhD. ... staff, preceptors, and students that participated in generating the ...
(Date:5/24/2013)... 2013 With Memorial Day Weekend upon us, ... is offering tips to help prevent grill fires throughout ... Association (NFPA) reports that gas grills led to an ... or other solid-fueled grills, meanwhile, caused approximately 1,200 home fires ... Amica Insurance is sharing the following tips from the NFPA ...
(Date:5/24/2013)... E-Dentists.com has announced the launch of their new ... a leading medical Internet marketing agency. , ... focus on providing dentists the help they need to ... keywords. The dental SEO analysis covers a full analysis ... their competitors are doing right. The goal is to ...
(Date:5/24/2013)... May 24 (HealthDay News) -- Drugs commonly used to ... effects that can interfere with vision, according to a ... (PGAs), which are used to reduce eye pressure, have ... changes in eye color, the researchers said, suggesting that ... PGAs. Doctors should be conservative when prescribing ...
Breaking Medicine News(10 mins):Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2
... for specific treatments, experts say , THURSDAY, March 11 ... pressure and stroke, new British research suggests that extremely ... can greatly increase a person,s risk of stroke. , ... simple hypertension is all that matters, but variability and ...
... Officials at the Natural Products Association (NPA), the leading U.S. trade organization ... between industry proponents Sens. Orrin Hatch (R-UT) and Tom Harkin ... ND) regarding McCain and Dorgan,s recently co-sponsored Dietary Safety Supplement Act (S.3002). , ... ...
... in this week,s issue of the Journal of the ... how he and other physicians who worked in Haiti after ... in the face of a crushing wave of patients and ... in the essay that the team of Johns Hopkins physicians ...
... individuals, DNA to get at causes of disease , ... teams announced this week that they had successfully sequenced ... -- breakthroughs that open the door to a future ... in the inevitable march towards personalized genetic health," said ...
... Ariz. March 11, 2010 Many women live ... treatment, a condition that researchers at the Virginia G. Piper ... targeting specific genes. Improving quality of life and potentially ... time are goals of a new clinical trial at the ...
... abuse testing lab to produce a kit explaining to lawyers how hair alcohol testing works. , ... , , ... ... ...
Cached Medicine News:Health News:Variable Blood Pressure a New Stroke Risk Factor? 2Health News:Variable Blood Pressure a New Stroke Risk Factor? 3Health News:Natural Products Association Welcomes Senate Deal on S.3002 2Health News:Natural Products Association Welcomes Senate Deal on S.3002 3Health News:Hopkins doctor/disaster expert says resource problems in Haiti required ethical decision-making 2Health News:Medicine's Future Could Lie in Each Patient's Genome 2Health News:Medicine's Future Could Lie in Each Patient's Genome 3Health News:Medicine's Future Could Lie in Each Patient's Genome 4Health News:Effort aims to spike breast cancer with new approach 2Health News:Hair Alcohol Test Kit to Help in Third of Care Cases 2Health News:Hair Alcohol Test Kit to Help in Third of Care Cases 3
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
Medicine Products: